Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village"

Purpose Of Review: Review international efforts to build a global public health initiative focused on toxoplasmosis with spillover benefits to save lives, sight, cognition and motor function benefiting maternal and child health.

Recent Findings: Multiple countries' efforts to eliminate toxoplasmosis demonstrate progress and context for this review and new work.

Summary: Problems with potential solutions proposed include accessibility of accurate, inexpensive diagnostic testing, pre-natal screening and facilitating tools, missed and delayed neonatal diagnosis, restricted access, high costs, delays in obtaining medicines emergently, delayed insurance pre-approvals and high medicare copays taking considerable physician time and effort, harmful shortcuts being taken in methods to prepare medicines in settings where access is restricted, reluctance to perform ventriculoperitoneal shunts promptly when needed without recognition of potential benefit, access to resources for care, especially for marginalized populations, and limited use of recent advances in management of neurologic and retinal disease which can lead to good outcomes.

Supplementary Information: The online version contains supplementary material available at 10.1007/s40124-022-00268-x.

Citing Articles

Mapping maternal and infant health in Morocco: A global scoping review of themes, gaps, and the "unseen" in the published health research literature, 2000-2022.

Amster E, Jessani G, Gupta G, Hlyva O, Rae C PLOS Glob Public Health. 2024; 4(7):e0003488.

PMID: 39024351 PMC: 11257357. DOI: 10.1371/journal.pgph.0003488.

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more.

Zhou Y, Leahy K, Grose A, Lykins J, Siddiqui M, Leong N PLoS Negl Trop Dis. 2024; 18(5):e0011335.

PMID: 38805559 PMC: 11132520. DOI: 10.1371/journal.pntd.0011335.

Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.

Felin M, Wang K, Moreira A, Grose A, Leahy K, Zhou Y Curr Pediatr Rep. 2022; 10(3):57-92.

PMID: 36034212 PMC: 9395898. DOI: 10.1007/s40124-022-00269-w.

References

McLeod R, Mack D, Boyer K, Mets M, Roizen N, Swisher C . Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med. 1990; 116(5):623-35. View

Mazumdar J, Wilson E, Masek K, Hunter C, Striepen B . Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci U S A. 2006; 103(35):13192-7. PMC: 1559775. DOI: 10.1073/pnas.0603391103. View

Tan T, Mui E, Cong H, Witola W, Montpetit A, Muench S . Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 2010; 28(23):3977-89. PMC: 2895808. DOI: 10.1016/j.vaccine.2010.03.028. View

Koppe J, LOEWER-SIEGER D, DE ROEVER-BONNET H . Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986; 1(8475):254-6. DOI: 10.1016/s0140-6736(86)90785-3. View

Lago E . Risk factors for congenital toxoplasmosis are not always obvious. Am J Obstet Gynecol. 2006; 194(3):907. DOI: 10.1016/j.ajog.2005.07.021. View

Swisher C, Boyer K, McLeod R . Congenital toxoplasmosis. The Toxoplasmosis Study Group. Semin Pediatr Neurol. 1994; 1(1):4-25. View

Mui E, Schiehser G, Milhous W, Hsu H, Roberts C, Kirisits M . Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008; 2(3):e190. PMC: 2254147. DOI: 10.1371/journal.pntd.0000190. View

Gomez-Marin J, Munoz-Ortiz J, Mejia-Oquendo M, Arteaga-Rivera J, Rivera-Valdivia N, Bohorquez-Granados M . High frequency of ocular toxoplasmosis in Quindío, Colombia and risk factors related to the infection. Heliyon. 2021; 7(4):e06659. PMC: 8056222. DOI: 10.1016/j.heliyon.2021.e06659. View

McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N . Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006; 42(10):1383-94. DOI: 10.1086/501360. View

10.

Vogel N, Kirisits M, Michael E, Bach H, Hostetter M, Boyer K . Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996; 23(5):1055-60. DOI: 10.1093/clinids/23.5.1055. View

11.

Lykins J, Filippova E, Halavaty A, Minasov G, Zhou Y, Dubrovska I . CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in . Front Cell Infect Microbiol. 2018; 8:352. PMC: 6182094. DOI: 10.3389/fcimb.2018.00352. View

12.

Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Bonithon Kopp C . Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013; 56(9):1223-31. DOI: 10.1093/cid/cit032. View

13.

Stillwaggon E, Carrier C, Sautter M, McLeod R . Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011; 5(9):e1333. PMC: 3181241. DOI: 10.1371/journal.pntd.0001333. View

14.

Moura L, Bahia-Oliveira L, Wada M, Jones J, Tuboi S, Carmo E . Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis. 2006; 12(2):326-9. PMC: 3373086. DOI: 10.3201/eid1202.041115. View

15.

Zuther E, Johnson J, Haselkorn R, McLeod R, Gornicki P . Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A. 1999; 96(23):13387-92. PMC: 23957. DOI: 10.1073/pnas.96.23.13387. View

16.

Mejia-Oquendo M, Marulanda-Ibarra E, Gomez-Marin J . Evaluation of the impact of the first evidence-based guidelines for congenital toxoplasmosis in Armenia (Quindío) Colombia: An observational retrospective analysis. Lancet Reg Health Am. 2023; 1:100010. PMC: 9904040. DOI: 10.1016/j.lana.2021.100010. View

17.

Witola W, Liu S, Montpetit A, Welti R, Hypolite M, Roth M . ALOX12 in human toxoplasmosis. Infect Immun. 2014; 82(7):2670-9. PMC: 4097613. DOI: 10.1128/IAI.01505-13. View

18.

Bela S, Dutra M, Mui E, Montpetit A, Oliveira F, Oliveira S . Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun. 2012; 80(12):4298-308. PMC: 3497418. DOI: 10.1128/IAI.00328-12. View

19.

Contopoulos-Ioannidis D, Wheeler K, Ramirez R, Press C, Mui E, Zhou Y . Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015; 61(12):1815-24. PMC: 4657536. DOI: 10.1093/cid/civ721. View

20.

Dando C, Schroeder E, Hunsaker L, Deck L, Royer R, Zhou X . The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol Biochem Parasitol. 2001; 118(1):23-32. DOI: 10.1016/s0166-6851(01)00360-7. View